Recruiting
Phase 2
Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
About this study
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.
- Condition
- Malignant Melanoma
- Tested
- 68Ga-PSMA
- Sponsor
- Royal Marsden NHS Foundation Trust
Who can join
- Age
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 18 years
- Eligible sex: Male
- Study condition: Malignant Melanoma
- Males ≥18 years of age
- Biopsy proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site
Exclusion 7
- Patients unable to give voluntary written informed consent to participate in this study
- Patients not willing to complete all the study assessments
- Patients who are females
- Patients who are taking androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists.
- Patients who have or have previously been diagnosed with prostate cancer
- Patients who have had Lu-177 PSMA therapy or barium studies within a period of 10 days prior to undergoing PSMA PET-CT scanning
- Patients not fluent in English
Where
1 site, 1 recruiting
The Royal Marsden NHS Foundation Trust
London, United Kingdom
Contact
-
Reyhaneh Sadegh Zadeh
020 7352 8171 reyhaneh.sadeghzadeh@rmh.nhs.uk
Potential match only. Final eligibility is determined by the study team.